Total Payments
$40,629
2024 Payments
$2,497
Companies
76
Transactions
1,057
Medicare Patients
5,057
Medicare Billing
$1.4M
Payment Breakdown by Category
Consulting$17,149 (42.2%)
Food & Beverage$17,068 (42.0%)
Other$4,520 (11.1%)
Travel$1,028 (2.5%)
Education$838.28 (2.1%)
Gifts$25.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $17,149 | 26 | 42.2% |
| Food and Beverage | $17,068 | 991 | 42.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,120 | 10 | 10.1% |
| Travel and Lodging | $1,028 | 6 | 2.5% |
| Education | $838.28 | 21 | 2.1% |
| Honoraria | $400.00 | 2 | 1.0% |
| Gift | $25.00 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $6,999 | 60 | $0 (2024) |
| Exelixis Inc. | $3,488 | 5 | $0 (2021) |
| Novocure Inc. | $3,144 | 11 | $0 (2019) |
| Incyte Corporation | $2,762 | 26 | $0 (2024) |
| Amgen Inc. | $2,412 | 68 | $0 (2023) |
| TAIHO ONCOLOGY, INC. | $2,250 | 2 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $2,015 | 121 | $0 (2024) |
| Puma Biotechnology, Inc. | $1,323 | 14 | $0 (2023) |
| Janssen Biotech, Inc. | $1,194 | 64 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,175 | 75 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,497 | 31 | TAIHO ONCOLOGY, INC. ($1,125) |
| 2023 | $4,269 | 179 | AstraZeneca Pharmaceuticals LP ($689.21) |
| 2022 | $4,970 | 153 | Incyte Corporation ($2,406) |
| 2021 | $6,633 | 132 | Exelixis Inc. ($1,470) |
| 2020 | $1,598 | 90 | Amgen Inc. ($219.50) |
| 2019 | $10,067 | 160 | AstraZeneca Pharmaceuticals LP ($2,501) |
| 2018 | $7,772 | 152 | AstraZeneca Pharmaceuticals LP ($2,462) |
| 2017 | $2,823 | 160 | AstraZeneca Pharmaceuticals LP ($401.45) |
All Payment Transactions
1,057 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $115.56 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Education | In-kind items and services | $25.95 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $19.31 | General |
| Category: Oncology | ||||||
| 08/14/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $115.82 | General |
| Category: Rare Disease | ||||||
| 06/12/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $119.70 | General |
| Category: Oncology | ||||||
| 05/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 02/22/2024 | TAIHO ONCOLOGY, INC. | INQOVI (Drug) | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| Category: Oncology | ||||||
| 02/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.70 | General |
| 02/20/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $17.19 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 02/16/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $13.47 | General |
| Category: Oncology | ||||||
| 02/14/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug), PLUVICTO | Food and Beverage | In-kind items and services | $23.89 | General |
| Category: Oncology | ||||||
| 02/13/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $17.32 | General |
| 02/08/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $11.52 | General |
| Category: Oncology | ||||||
| 02/05/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $21.68 | General |
| Category: Oncology | ||||||
| 02/05/2024 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $16.52 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 02/01/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: ONCOLOGY | ||||||
| 02/01/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 01/31/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $13.39 | General |
| Category: Oncology | ||||||
| 01/29/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $25.69 | General |
| Category: ONCOLOGY | ||||||
| 01/24/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $20.17 | General |
| Category: Oncology | ||||||
| 01/24/2024 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $17.95 | General |
| 01/23/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $14.16 | General |
| Category: ONCOLOGY | ||||||
| 01/22/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $13.38 | General |
| Category: Immunology | ||||||
| 01/18/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: Oncology | ||||||
| 01/16/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 1,251 | 2,109 | $1.2M | $347,623 |
| 2022 | 13 | 1,142 | 1,915 | $1.0M | $308,754 |
| 2021 | 15 | 1,189 | 1,999 | $1.1M | $326,361 |
| 2020 | 14 | 1,475 | 2,677 | $1.4M | $412,937 |
Total Patients
5,057
Total Services
8,700
Medicare Billing
$1.4M
Procedure Codes
58
All Medicare Procedures & Services
58 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 143 | 227 | $826,280 | $225,753 | 27.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 249 | 520 | $44,618 | $30,245 | 67.8% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 150 | 243 | $136,688 | $23,612 | 17.3% |
| 78816 | Nuclear medicine study whole body with ct scan | Office | 2023 | 12 | 19 | $69,160 | $19,368 | 28.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 104 | 200 | $24,501 | $17,350 | 70.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 193 | 276 | $16,044 | $10,364 | 64.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 47 | 47 | $6,691 | $4,429 | 66.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 32 | 32 | $5,716 | $4,236 | 74.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 20 | $5,888 | $2,615 | 44.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 26 | 27 | $6,924 | $2,549 | 36.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 176 | 313 | $6,104 | $2,547 | 41.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 27 | $4,490 | $1,550 | 34.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 17 | $3,985 | $1,525 | 38.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 39 | 100 | $4,600 | $722.95 | 15.7% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 17 | 25 | $1,125 | $398.64 | 35.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 12 | 16 | $720.05 | $358.94 | 49.8% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2022 | 138 | 213 | $775,320 | $218,639 | 28.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 237 | 516 | $40,457 | $28,448 | 70.3% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2022 | 144 | 228 | $128,250 | $22,603 | 17.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 227 | 381 | $19,953 | $13,894 | 69.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 96 | 153 | $16,807 | $12,313 | 73.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 30 | 30 | $4,954 | $3,904 | 78.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 35 | 35 | $4,488 | $3,361 | 74.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 16 | 17 | $3,765 | $1,729 | 45.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 26 | $3,122 | $1,396 | 44.7% |
About Dr. Emmanuel Nidhiry, M.D
Dr. Emmanuel Nidhiry, M.D is a Hematology & Oncology healthcare provider based in Louisville, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255383162.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Emmanuel Nidhiry, M.D has received a total of $40,629 in payments from pharmaceutical and medical device companies, with $2,497 received in 2024. These payments were reported across 1,057 transactions from 76 companies. The most common payment nature is "Consulting Fee" ($17,149).
As a Medicare-enrolled provider, Nidhiry has provided services to 5,057 Medicare beneficiaries, totaling 8,700 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 58 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology, Hematology & Oncology
- Location Louisville, KY
- Active Since 05/17/2006
- Last Updated 03/18/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1255383162
Products in Payments
- Oncology (Device) $3,144
- MONJUVI (Drug) $2,426
- LYNPARZA (Drug) $2,300
- FASLODEX (Drug) $2,100
- Cabometyx (Drug) $2,018
- CABOMETYX (Drug) $1,470
- Nerlynx (Drug) $1,226
- INQOVI (Drug) $1,125
- Lonsurf (Drug) $1,125
- KEYTRUDA (Biological) $976.74
- CALQUENCE (Drug) $839.58
- Aliqopa (Drug) $800.00
- TAGRISSO (Drug) $794.81
- IMFINZI (Biological) $585.65
- OPDIVO (Biological) $548.74
- KISQALI (Drug) $526.29
- IMBRUVICA (Drug) $506.53
- Tepmetko (Drug) $500.00
- DARZALEX (Biological) $490.80
- ZEPZELCA (Drug) $480.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Louisville
Goetz Kloecker, Md, MD
Hematology & Oncology — Payments: $761,985
Hematology & Oncology $761,985
Vivek Sharma, Md, MD
Hematology & Oncology — Payments: $594,741
Hematology & Oncology $594,741
Dr. Khuda Khan, M.d., Ph.d, M.D., PH.D
Hematology & Oncology — Payments: $446,138
Hematology & Oncology $446,138
Dr. Jeffrey Hargis, M.d, M.D
Hematology & Oncology — Payments: $430,805
Hematology & Oncology $430,805
Dr. Joseph Maly, M.d, M.D
Hematology & Oncology — Payments: $43,035
Hematology & Oncology $43,035
Dharamvir Jain, Md, MD
Hematology & Oncology — Payments: $26,287
Hematology & Oncology $26,287